Galecto Biotech AB

Galecto Biotech (Lund, Sweden) is an early-stage orphan drug development company focusing on novel therapeutics for fibrosis and inflammatory-related diseases, including the lung disease Idiopathic Pulmonary Fibrosis (IPF). The lead program is in pre-clinical development and addresses a novel therapeutic target for IPF called Galectin-3.

http://www.galecto.com
Søren Lemonius

Partner

Mobile: +45 40 81 48 89
Email Click here to contact